Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Valneva SE - American Depositary Shares
(NQ:
VALN
)
10.08
+0.06 (+0.60%)
Streaming Delayed Price
Updated: 3:59 PM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Valneva SE - American Depositary Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
↗
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
April 25, 2022
Via
Benzinga
Valneva Receives More Questions From European Regulator For Its COVID-19 Vaccine, Shares Fall
↗
April 25, 2022
Via
Benzinga
Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years
↗
April 14, 2022
Via
Benzinga
Valneva Shares Jump As Its COVID-19 Vaccine Receives Conditional Approved In UK
↗
April 14, 2022
Via
Benzinga
Read Why Valneva's Stock Gained 7% Today
↗
March 08, 2022
Valneva SE (NASDAQ: VALN) completed the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. Valneva posted topline results ...
Via
Benzinga
Why Are Valneva Shares Rising Today Premarket?
↗
February 03, 2022
Valneva SE (NASDAQ: VALN) expects its COVID-19 vaccine candidate to boost its sales in FY22 considerably, after
Via
Benzinga
Valneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In Adolescents
↗
February 01, 2022
Valneva SE (NASDAQ: VALN) has
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
↗
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For March 24, 2022
↗
March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to...
Via
Benzinga
European Recommendation On Valneva's COVID-19 Shot Pushed Into April
↗
March 11, 2022
Valneva SE (NASDAQ: VALN) now expects a positive recommendation from the European Medicines Agency (EMA) for its VLA2001 COVID-19 candidate vaccine in April. Earlier,...
Via
Benzinga
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China
↗
March 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of Conditional Approval For COVID Vaccine Candidate In...
Via
Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
↗
March 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...
Via
Benzinga
42 Stocks Moving in Monday's Pre-Market Session
↗
March 07, 2022
Gainers Nine Energy Service, Inc. (NYSE: NINE) rose 96.7% to $3.54 in pre-market trading after climbing around 43% on Friday. Shares of low-priced energy stocks jumped as...
Via
Benzinga
76 Biggest Movers From Yesterday
↗
March 08, 2022
Gainers Houston American Energy Corp. (NYSE: HUSA) surged 494.7% to close at $11.30 on Monday amid continued momentum and an increase in the price of oil. Imperial Petroleum Inc...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
↗
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
46 Stocks Moving In Monday's Mid-Day Session
↗
March 07, 2022
Gainers Houston American Energy Corp. (NYSE: HUSA) jumped 137.4% to $4.5150 amid continued momentum and an increase in the price of oil. Imperial Petroleum Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
↗
February 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...
Via
Benzinga
Valneva Secures £20M From Scottish Enterprise For Vaccine Development
↗
February 22, 2022
Valneva SE (NASDAQ: VALN) has been awarded research and development funding of up to £20 million by Scottish Enterprise. The investment from Scotland's...
Via
Benzinga
Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward
↗
February 04, 2022
Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have
Via
Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
↗
February 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
↗
February 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
February 03, 2022
Good morning, trader! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
↗
February 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
↗
January 25, 2022
Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is...
Via
Benzinga
48 Biggest Movers From Yesterday
↗
January 21, 2022
Gainers Aptorum Group Limited (NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company announced it received FDA Orphan Drug designation for...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
January 20, 2022
Gainers Aptorum Group (NASDAQ:APM) stock increased by 32.8% to $1.62 during Thursday's regular session. Aptorum Group's stock is trading at a volume of 86.4...
Via
Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
↗
January 20, 2022
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 29.8% to $0.2550. Baudax Bio, last month, announced a $4.2 million registered direct offering. Vertical Aerospace Ltd. (NYSE...
Via
Benzinga
Mid-Morning Market Update: Markets Open Higher; American Airlines Posts Narrower-Than-Expected Loss
↗
January 20, 2022
Following the market opening Thursday, the Dow traded up 0.92% to 35,352.17 while the NASDAQ rose 1.61% to 14,570.49. The S&P also rose, gaining, 1.06% to 4,581.00. The U.S....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
January 20, 2022
Gainers Baudax Bio (NASDAQ:BXRX) stock rose 32.2% to $0.26 during Thursday's pre-market session. The company's market cap stands at $21.9 million. Aptorum Group (...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.